Screener
Allogene Therapeutics ALLO Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $4,933 | $4,270 |
| Accrued and other current liabilities | 23,397 | 28,244 |
| Total current liabilities | 28,330 | 32,514 |
| Lease liability, noncurrent | 72,633 | 75,045 |
| Other long-term liabilities | 16,120 | 15,804 |
| Total liabilities | 117,083 | 123,363 |
| Commitments and Contingencies (Notes 6 and 7) |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's total current liabilities?
- Allogene Therapeutics (ALLO) reported total current liabilities of $28.33M in Q1 2026.
- How has Allogene Therapeutics's total current liabilities changed year-over-year?
- Allogene Therapeutics's total current liabilities decreased by 5.6% year-over-year, from $30.02M to $28.33M.
- What is the long-term trend for Allogene Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Allogene Therapeutics's total current liabilities has grown at a -19.2% compound annual growth rate (CAGR), from $94.32M to $32.51M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Allogene Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude